Pharmaceutical uses and synthesis of nicotinanilide-N-oxides

Details Pharmaceutical uses and synthesis of nicotinanilide-N-oxides Pharmaceutical uses and synthesis of nicotinanilide-N-oxides

2006-11-28

2006-11-28

Desai, Rita J. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S347000

Reexamination Certificate

active

07141590

ABSTRACT:
Disclosed are nicotinanilide-N-oxide compounds, methods for their production, pharmaceutical compositions which include these compounds, and methods for their use in various therapies.

REFERENCES:
patent: 3637716 (1972-01-01), Bimber et al.
patent: 3766195 (1973-10-01), Bimber et al.
patent: 3950160 (1976-04-01), Abu El-Haj et al.
patent: 4055427 (1977-10-01), Bergthaller et al.
patent: 4730051 (1988-03-01), Ueda et al.
patent: 4787931 (1988-11-01), Henrie et al.
patent: 4978385 (1990-12-01), Yagihara et al.
patent: 4990518 (1991-02-01), Khanna et al.
patent: 5472687 (1995-12-01), Proctor
patent: 6022884 (2000-02-01), Mantlo et al.
patent: 6333341 (2001-12-01), Mantlo et al.
patent: 6794397 (2004-09-01), Cai et al.
patent: 2538950 (1977-03-01), None
patent: 1134651 (1968-11-01), None
patent: WO 98/07692 (1998-02-01), None
patent: WO 99/07380 (1999-02-01), None
patent: WO 99/62885 (1999-12-01), None
patent: WO 01/14340 (2001-03-01), None
patent: WO 01/55115 (2001-08-01), None
patent: WO 02/22599 (2002-03-01), None
Caplus, English Abstract DN 81:169412, Schnekenburger, Joerg et al 1974.
English Abstract, Caplus DN 75:75600 Intramolecular hydrogen bond . . . by Mirek, Julian et al (1971), 45(2), 205-900.
English Abstract, Caplus, DN 128:289722, Structure and anti-inflammatory . . . Bukhtiarova, T. A.et al (1997), 31(11), 30-32.
English Abstract DN 133:135326, Preparation of amide . . . ,Miyahara, Osamu et , JP 2000226372, Aug. 15, 2000.
DN 132:22963, Preparation of N-(pyrazolylphenyl)alkanamides and analogs as IL-2 production inhibitors, Betageri, Rajashekhar et al, WO 9962885, Dec. 9, 1999.
Caplus English abstract DN 127:331402, Preparation of pyridine-2,3-dicarboxamides.., Tonishi, Masanori et al .EP 799825 A1, Oct. 8, 1997.
DN 127:51002. WO 9717070, Sebti Said et al, May 15, 1997.
JP 63017811 Yagihara, Hiromu. English Abstract DN 109:68852, Jan. 25, 1988.
English Abstract DN 97:215892 Penicillin derivs. and their salts JP 57109792, Jul. 8, 1982.
English abstract DN 87:5812, SU 539878, 1976, Otkrytiya, Izobret. Et al, Dec. 25, 1976.
Danilenko, G. I. Antiinflammatory action . . . English abstract DN 89:89560. 1976.
Ca plus English abstract 110:154162 EP 292990. Yagihara, Hiroshi et al, Nov. 30, 1988.
Caplus , English Abstract DN 86:15920 Brzezinski Bogumil 1976.
Caplus , English Abstract DN 83:96958 Brzezinski B et al 1975.
Caplus English Abstract DN 97:144206 Brzezinski wt al 1982.
Santamaria Babi et al., “The interleukin-8 receptor B and CXC chemokines can mediate transendothelial migration of human skin homing T cells,”Eur. J. Immunol. 26(9):2056-2061, Sep. 1996.
Besemer et al., “Specific binding, internalization, and degradation of human neutrophil activating factor by human polymorphonuclear leukocytes,”J. Biol. Chem. 264(29):17409-17415, Oct. 15, 1989.
Boisvert et al., “A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice,”J. Clin. Invest. 101(2):353-363, Jan. 15, 1998.
Chuntharapai et al., “Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes,”J. Immunol. 153(12):5682-5688, Dec. 15, 1994.
Chuntharapai et al., “Regulation of the expression of IL-8 receptor A/B by IL-8: possible functions of each receptor,”J Immunol 155(5):2587-2594, Sep. 1, 1995.
Cummings et al., “Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis,”J. Immunol. 162(4):2341-6, Feb. 15, 1999.
Donnelly Robertson, “Mediators, mechanisms and mortality in major trauma,”Resuscitation 28(2):87-92, Oct. 1994.
Donnelly and Robertson, “Trauma, inflammatory cells and ARDS,”Arch. Emerg. Med. 10(2):108-11, Jun. 1993.
Endo et al., “Elevation of interleukin-8 (IL-8) levels in joint fluids of patients with rheumatoid arthritis and the induction by IL-8 of leukocyte infiltration and synovitis in rabbit joints,”Lymphokine and Cytokine Research 10(4):245-252, Aug. 1991.
Fuhlendorff et al., “[Leu31, Pro34]Neuropeptide Y: a specific Y1receptor agonist,”PNAS USA 87(1):182-186, Jan. 1990.
Gillitzer et al., “Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo,” J. Invest. Dermatol. 107(5):778-782, Nov. 1996.
Goldman et al., “Tumor Necrosis Factor-α Mediates Acid Aspiration-induced Systemic Organ Injury,”Ann. Surg. 212(4):513-520, Oct. 1990.
Goodman et al., “Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome,”Am. J. Respir. Crit. Care Med. 154(3 Pt 1):602-611, Sep. 1996.
Grob et al., “Characterization of a receptor for human monocyte-derived neutrophil chemotactic factor/interleukin-8,”J. Biol. Chem. 265(14):8311-8316, May 15, 1990.
Hammond et al., “IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors,”J. Immunol. 155(3):1428-1433, Aug. 1, 1995.
Holmes et al., “Structure and functional expression of a human interleukin-8 receptor,”Science 253(5025):1278-1280, Sep. 13, 1991.
Horuk et al., “Expression of chemokine receptors by subsets of neurons in the central nervous system,”J. Immunol. 158(6):2882-2890, Mar. 15, 1997.
Izzo et al., “Interleukin-8 and neutrophil markers in colonic mucosa from patients with ulcerative colitis,”Am. J. Gastroenterology 87(10):1447-1452, Oct. 1992.
Jones et al., “Chemokine antagonists that discriminate between interleukin-8 receptors. Selective blockers of CXCR2,”J. Biol. Chem. 272(26):16166-16169, Jun. 27, 1997.
Kojima et al., “GRO-α mRNA is selectively overexpressed in psoriatic epidermis and is reduced by cyclosporin A in vivo, but not in cultured keratinocytes,”J. Invest. Dermatology 101(6):767-772, Dec. 1993.
Linas et al., “Neutrophils accentuate ischemia-reperfusion injury in isolated perfused rat kidneys,”Am. J. Physiology 255(4 Pt 2):F728-F735, Oct. 1988.
Mahida et al., “Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active ulcerative colitis,”Clinical Science(London) 82(3):273-275, Mar. 1992.
Matsukawa et al., “Involvement of growth-related protein in lipopolysaccharide-induced rabbit arthritis: cooperation between growth-related protein and IL-8, and interrelated regulation among TNFα, IL-1, IL-1 receptor antagonist, IL-8, and growth-related protein,”Laboratory Investigation 79(5):591-600, May 1999.
Murphy and Tiffany, “Cloning of Complementary DNA Encoding a Functional Human Interleukin-8 Receptor,”Science 253(5025):1278-1280. Sep. 13, 1991.
Quan et al., “Antibodies against the N-terminus of IL-8 receptor A inhibit neutrophil chemotaxis,”Biochemical Biophysical Research Communications 219(2):405-411, Feb. 15, 1996.
Repine and Beechler, “Neutropils and Adult Respiratory Distress Syndrome: Two Interlocking Perspectives in 1991,”Am. Rev. Respir. Dis. 144:251-252, 1991.
Samanta et al., “Identification and characterization of specific receptors for monocyte-derived neutrophil chemotactic factor (MDNCF) on human neutrophils,”J. Exp. Med. 169(3):1185-1189, Mar. 1, 1989.
Samson et al., “The second extracellular loop of CCR5 is the major determinant of ligand specificity,”J. Biol. Chem. 272(40):24934-24941, Oct. 3, 1997.
Schwartz et al., “Role of the GRO family of chemokines in monocyte adhesion to MM-LDL-stimulated endothelium,”J. Clin. Invest. 94(5):1968-1973, Nov. 1994.
Sheikh et al., “Binding of monoiodinated neuropeptide Y to hippocampal membranes and human neuroblastoma cell lines,”J. Biol. Chem. 264(12):6648-6654, Apr. 25, 1989.
Simpson and Hechtman, “Pulmonar Injury Following Sepsis,”Prog. Clin. Biol. Res. 388:265-275, 1994.
Srikant and Heisler, “Relationship between receptor binding

Affiliated with

Also associated with

Rating

Pharmaceutical uses and synthesis of nicotinanilide-N-oxides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical uses and synthesis of nicotinanilide-N-oxides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical uses and synthesis of nicotinanilide-N-oxides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3699763